Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.55 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | CPA3 | P15088 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7806170 | 0.88 | KMT2A (0.46) | CPA1CPB1CPA3CPB2POLB | |
| SCHEMBL6178867 | 0.80 | LDHA (0.67) | CPA1CPB1CPA3CPB2FOLH1 | |
| SCHEMBL6179718 | 0.80 | FFAR1 (0.40) | POLBLDHAMMP1MMP2MMP3 | |
| SCHEMBL17537907 | 0.79 | CPA1 (0.84) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL15033738 | 0.79 | POLB (0.46) | POLB | |
| SCHEMBL29129646 | 0.75 | PPARG (0.57) | CPA1CPB1CPA3CPB2POLB | |
| SCHEMBL2533621 | 0.75 | CPA1 (0.70) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL17693395 | 0.75 | CPA1 (0.70) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL10824132 | 0.73 | CPA1 (0.68) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL3205288 | 0.73 | CPA1 (0.72) | CPA1CPB1CPA3CPB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881736-B1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1218005-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | CPA1 412/4885CPB1 670/4885CPA3 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.